Biotech News

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

Liquidia Corporation (LQDA)Liquidia Corporation2026-09-02 12:30 ESTCompany update

MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the

Related news

LQDALiquidia Corporation2026-01-27 13:30 EST

Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress

LQDALiquidia Corporation2026-05-27 12:30 EST

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

View all latest news

Liquidia Corporation

Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved...

Recent company news

LQDALiquidia Corporation2026-09-30 17:20 EST

Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent

LQDALiquidia Corporation2026-09-03 11:30 EST

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

LQDALiquidia Corporation2026-09-02 12:30 EST

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

LQDALiquidia Corporation2026-09-01 12:30 EST

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

LQDALiquidia Corporation2026-08-12 10:30 EST

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Stock data

Close: 27.99 USD
Market cap: 4.9B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States